New FDA-Approved Oncology Drugs/Indications.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 5, p. 283
- Publication type:
- Article
Works matching IS 21641153 AND DT 2022 AND VI 12 AND IP 5
Results: 8
1
2
Complete Pathologic Response to Pembrolizumab in a Patient with Cutaneous Angiosarcoma: Case Report.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 5, p. 278
- By:
- Publication type:
- Article
3
Isavuconazonium Sulfate Dosing in Pediatric Patients Using Serum Therapeutic Drug Monitoring at a Single Center: A Case Series.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 5, p. 271
- By:
- Publication type:
- Article
4
Evaluating Institutional Safety Standards Related to Continuing Oral Antineoplastic Medication Use During Hospitalization.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 5, p. 264
- By:
- Publication type:
- Article
5
Biden's Cancer 'Moonshot' Contradiction.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 5, p. 263
- Publication type:
- Article
6
Implementation and Evaluation of a Formal Investigational Drug Service at a Community Cancer Center.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 5, p. 256
- By:
- Publication type:
- Article
7
Impact of Pharmacist Telephone Follow-Up on Chemotherapy-Induced Nausea and Vomiting.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 5, p. 248
- By:
- Publication type:
- Article
8
Time to First Palbociclib Prescription Dispense at Mayo Clinic: Comparing a Health-System Specialty Pharmacy with External Specialty Pharmacies.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 5, p. 241
- By:
- Publication type:
- Article